# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001140361-26-023583
Filing Date
2026-06-01
Accepted
2026-06-01 17:00:21
Documents
4
Period of Report
2026-07-16

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | ny20071594x2_def14a.htm | DEF 14A | 345302
2 |  | logo_outlookthera.jpg | GRAPHIC | 52140
3 |  | ny20071594x2_pc01.jpg | GRAPHIC | 767659
4 |  | ny20071594x2_pc02.jpg | GRAPHIC | 457273
| Complete submission text file | 0001140361-26-023583.txt |  | 2104555

Mailing Address 111 S. WOOD AVENUE UNIT #100 ISELIN NJ 08830
Business Address 111 S. WOOD AVENUE UNIT #100 ISELIN NJ 08830 6096193990
Outlook Therapeutics, Inc. (Filer) CIK: 0001649989 (see all company filings)

EIN.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
Type: DEF 14A | Act: 34 | File No.: 001-37759 | Film No.: 261052098
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)